IL6 and COVID-19: Upper-airway-related symptoms are commonly observed in patients with both COVID-19 and Self-RPD+, potentially representing the primary mechanism responsible for sustaining elevated IL-6 levels in this group, compared to patients with COVID-19 alone, Self-RPD+ alone, or healthy controls.